Mouse Model News and Research

RSS

Hedgehog and mTOR pathway are active in esophageal cancer

Identification of a non-traditional pathway for spiriting a cancer-promoting protein into the cell nucleus points to a possible combination therapy for esophageal cancer and indicates a mechanism of resistance for new drugs that attack the Hedgehog pathway.

20 Mar 2012

NIH awards Avaxia $1.5M Phase II SBIR grant to develop antibody therapeutic for IBD

Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody therapeutics for the treatment of gastrointestinal diseases, is proud to announce that it has received a second round of funding from the National Institutes of Health for its work in inflammatory bowel disease.

19 Mar 2012

Two awards to advance pancreatic cancer research

The Pancreatic Cancer Action Network and the American Association for Cancer Research have awarded Stephanie K. Dougan, Ph.D., postdoctoral fellow at the Whitehead Institute for Biomedical Research, and Oliver G. McDonald, M.D., Ph.D., postdoctoral fellow at Johns Hopkins University, the 2012 Pancreatic Cancer Action Network-AACR Pathway to Leadership Grants.

16 Mar 2012

GABA neurons could help restore muscle coordination deficits of Huntington's

Huntington's disease, the debilitating congenital neurological disorder that progressively robs patients of muscle coordination and cognitive ability, is a condition without effective treatment, a slow death sentence. But if researchers can build on new research reported this week in the journal Cell Stem Cell, a special type of brain cell forged from stem cells could help restore the muscle coordination deficits that cause the uncontrollable spasms characteristic of the disease.

16 Mar 2012

OHRI, uOttawa to lead first stem cell therapy trial for septic shock

A team of researchers from the Ottawa Hospital Research Institute (OHRI) and the University of Ottawa (uOttawa) has been awarded $367,000 from the Canadian Institutes of Health Research (CIHR) and $75,000 from the Stem Cell Network to lead the first clinical trial in the world of a stem cell therapy for septic shock.

16 Mar 2012

CUMC scientists develop a way to recreate personalized immune mouse

Columbia University Medical Center (CUMC) scientists have developed a way to recreate an individual's immune system in a mouse. The "personalized immune mouse" offers researchers an unprecedented tool for individualized analysis of abnormalities that contribute to type 1 diabetes and other autoimmune diseases, starting at the onset of disease.

15 Mar 2012

Scientists report about a brain circuit that mediates loss of appetite

The meal is pushed way, untouched. Loss of appetite can be a fleeting queasiness or continue to the point of emaciation. While it's felt in the gut, more is going on inside the head. New findings are emerging about brain and body messaging pathways that lead to loss of appetite, and the systems in place to avoid starvation.

15 Mar 2012

Researchers discover over 500 genes that may contribute to pancreatic cancer

A global team led by scientists from The Methodist Hospital Research Institute has identified more than 500 genes that may cause or contribute to the development of pancreatic cancer.

13 Mar 2012

JAK-STAT inhibitors reverse MS-like disease in mice

A new class of drugs completing clinical trials soon for rheumatoid arthritis should be examined as a treatment for multiple sclerosis, according to the authors of a University of Alabama at Birmingham study published today in the Proceedings of the National Academy of Sciences.

13 Mar 2012

Allon advances into second phase of work in preclinical PD model

Allon Therapeutics Inc. announced today the completion of its first phase of work in a preclinical Parkinson's disease model and advancement into the second phase of work. Both phases are funded by The Michael J. Fox Foundation for Parkinson's Research and carried out by Prof. Marie-Francoise Chesselet's lab at the University of California Los Angeles.

12 Mar 2012

HIPK2 regulator protein plays a crucial role in kidney fibrosis

Researchers from Mount Sinai School of Medicine have identified a regulator protein that plays a crucial role in kidney fibrosis, a condition that leads to kidney failure. Finding this regulator provides a new therapeutic target for the millions of Americans affected by kidney failure. The research is published in the March 11 issue of Nature Medicine.

12 Mar 2012

XMetA can control blood glucose levels in patients with diabetes

XOMA Corporation announced that its study of XMetA, the company's fully-human allosteric monoclonal antibody to the insulin receptor, is available online and will be published in the May issue of the American Diabetes Association's journal Diabetes.

8 Mar 2012

Doctors identify promising new treatment for hypophosphatasia

Doctors at Washington University School of Medicine in St. Louis, working with Shriners Hospital for Children and other institutions, have identified a promising new treatment for a rare and sometimes life-threatening bone disorder that can affect infants and young children.

8 Mar 2012

Researchers identify key molecular player in mouse model of kidney disease

In findings that may lead to clinical trials of a promising new drug for kidney disease, researchers at Beth Israel Deaconess Medical Center (BIDMC) and their colleagues have identified a key molecular player and shown how a targeted experimental drug can reverse kidney damage in mouse models of diabetes, high blood pressure, genetic kidney disease, and other kidney injuries.

8 Mar 2012

Researchers make significant strides in the study of Intrahepatic Cholangiocarcinoma

Researchers at the University of Rochester Medical Center's James P. Wilmot Cancer Center have made significant strides in the study of a primary cancer of the liver- Intrahepatic Cholangiocarcinoma (IHCC), also called biliary tract cancer.

8 Mar 2012

Researchers validate CatB protease as target for Alzheimer's

Researchers at the University of California, San Diego, the Medical University of South Carolina, the University of Cincinnati, and American Life Science Pharmaceuticals of San Diego have validated the protease cathepsin B (CatB) as a target for improving memory deficits and reducing the pathology of Alzheimer's disease (AD) in an animal model representative of most AD patients.

8 Mar 2012

New breakthrough in early mammalian embryo development

Pioneering work by a leading University of Nottingham scientist has helped reveal for the first time a vital process in the development of the early mammalian embryo.

3 Mar 2012

CLR01 blocks toxic aggregations of proteins in mouse model of Parkinson's

Millions of people suffer from Parkinson's disease, a disorder of the nervous system that affects movement and worsens over time. As the world's population ages, it's estimated that the number of people with the disease will rise sharply. Yet despite several effective therapies that treat Parkinson's symptoms, nothing slows its progression.

2 Mar 2012

New link between polyamine regulation and ESC biology

A*STAR scientists have for the first time, identified that precise regulation of polyamine levels is critical for embryonic stem cell (ESC) self-renewal - the ability of ESCs to divide indefinitely - and directed differentiation.

2 Mar 2012

Loss of STAT1 transcription factor causes breast cancer development

Breast cancer represents about a fifth of all cancers diagnosed in women. The reasons for the rapid progression of the disease remain relatively poorly understood but recent work in the group of Veronika Sexl at the University of Veterinary Medicine, Vienna has pointed the finger strongly at loss or inactivation of the transcription factor STAT1.

1 Mar 2012